In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors
Public ClinicalTrials.gov record NCT04616248. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase I Study of In Situ Immunomodulation With CDX-301, Radiotherapy, CDX-1140, and Poly-ICLC in Patients With Unresectable and Metastatic Solid Tumors With Injectable Palpable Disease
Study identification
- NCT ID
- NCT04616248
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- University of Southern California
- Other
- Enrollment
- 14 participants
Conditions and interventions
Conditions
- Anatomic Stage IV Breast Cancer AJCC v8
- Basal Cell Carcinoma
- Bone Sarcoma
- Cutaneous Squamous Cell Carcinoma
- Merkel Cell Carcinoma
- Metastatic Breast Carcinoma
- Metastatic Melanoma
- Prognostic Stage IV Breast Cancer AJCC v8
- Sarcoma of Bone
- Sarcoma,Soft Tissue
- Soft Tissue Sarcoma
- Unresectable Breast Carcinoma
- Unresectable Melanoma
Interventions
- Anti-CD40 Agonist Monoclonal Antibody CDX-1140 Biological
- Pembrolizumab Drug
- Poly ICLC Drug
- Radiation Therapy Radiation
- Recombinant Flt3 Ligand Biological
- Tocilizumab Drug
Biological · Drug · Radiation
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 8, 2023
- Primary completion
- Jan 8, 2027
- Completion
- Jan 8, 2028
- Last update posted
- Jan 6, 2026
2023 – 2028
United States locations
- U.S. sites
- 2
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Los Angeles General Medical Center | Los Angeles | California | 90033 | — |
| USC/Norris Comprehensive Cancer Center | Los Angeles | California | 90033 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04616248, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 6, 2026 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04616248 live on ClinicalTrials.gov.